Nikhil Khandelwal

Takeda Pharmaceuticals USA, Inc.

Poster(s):

• (244) Healthcare costs associated with the care of patients with chronic inflammatory demyelinating polyneuropathy receiving immunoglobulin or neonatal fragment crystallizable receptor inhibitor therapies in the US
  Wednesday, October 29, 2025